GTS Securities’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,533
Closed -$20.5K 4134
2024
Q2
$20.5K Sell
1,533
-480
-24% -$14.3K ﹤0.01% 3789
2024
Q1
$93.4K Sell
2,013
-232
-10% -$12K ﹤0.01% 3535
2023
Q4
$152K Buy
2,245
+785
+54% +$48.1K ﹤0.01% 3656
2023
Q3
$106K Buy
+1,460
New +$117K ﹤0.01% 3591

Other funds holding DNA

GTS Securities's DNA Position: Q3 2024 in Review

GTS Securities sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 6,086 shares — an estimated $61K sold.

GTS Securities first reported a position in DNA in Q2 2023 and held it in 5 quarters. The position peaked at $419K in Q2 2023. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • GTS Securities reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 6,086 Ginkgo Bioworks shares in Q3 2024, an estimated $61K.
  • GTS Securities first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 5 quarters.
  • GTS Securities's Ginkgo Bioworks position peaked at $419K in Q2 2023.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.